Pharma Journalist -

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced the clearance of…
Read More...

Panbela Therapeutics, Inc. announced that it has regained the North American rights to develop and commercialize Flynpovi (the combination of CPP-1X (eflornithine) and sulindac) in…
Read More...

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that it has successfully discovered a potent,…
Read More...

Centogene N.V. announced it has extended its partnership with Takeda to diagnose patients with Lysosomal Storage Disorders (LSDs). Under the renewed one-year partnership agreement,…
Read More...

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) for BRAFTOVI® (encorafenib) + MEKTOVI® …
Read More...

Fixing our broken system demands we connect disparate data, streamline clinical workflows, and zero in on consumer orientated, digitally enabled care delivery. Yet just how much…
Read More...

Sandoz, a global leader in off-patent (generic and biosimilar) medicines, announced that the European Commission (EC) granted marketing authorization in the European Union (EU) for a…
Read More...

BioNTech SE and Duality Biologics (Suzhou) Co. Ltd., a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate (“ADC”)…
Read More...

Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with…
Read More...

Novartis announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Entresto…
Read More...